Hoppas (Treprostinil)

Hoppas is indicated for the management of pulmonary arterial hypertension (PAH) in adult patients when oral therapies are insufficient or not tolerated. It is used as part of a comprehensive treatment plan aimed at improving exercise capacity and delaying disease progression.

• Initiated in patients with WHO functional class II–IV PAH who require prostacyclin therapy.
• Administered via continuous intravenous infusion for rapid onset of action.
• Can be delivered subcutaneously for patients preferring an alternative route.
• Used in combination with other PAH‑specific agents such as endothelin receptor antagonists or phosphodiesterase‑5 inhibitors.
• Adjusted based on clinical response, hemodynamic measurements, and tolerability.

• Treprostinil is a synthetic analog of prostacyclin that selectively activates the prostacyclin (IP) receptor on vascular smooth‑muscle cells. Receptor activation stimulates adenylate cyclase, increasing intracellular cyclic‑AMP levels, which leads to relaxation of pulmonary arterial smooth muscle and inhibition of platelet aggregation. The resulting vasodilation reduces pulmonary vascular resistance and improves cardiac output in patients with pulmonary arterial hypertension and contributes to remodeling reversal.

Adverse reactions to treprostinil may vary in frequency and severity. Patients should be monitored for both common and potentially serious events during therapy.

Common

• Headache, flushing, or warmth sensation at the infusion site.
• Diarrhea, nausea, or abdominal discomfort.
• Jaw pain or muscle aches, especially during dose titration.
• Peripheral edema or swelling of the extremities.
• Dyspepsia or heartburn.
• Insomnia or difficulty sleeping.

Serious

• Severe hypotension or syncope requiring medical intervention.
• Pulmonary hemorrhage or hemoptysis.
• Infections related to the infusion catheter, such as sepsis or thrombophlebitis.
• Cardiac arrhythmias, including tachycardia or atrial fibrillation.
• Renal impairment or worsening kidney function.
• Liver enzyme elevations indicating hepatic stress.

When prescribing treprostinil, clinicians should consider several precautions to minimize risk and ensure safe use.

• Assess baseline hemodynamics and right‑heart function before initiating therapy.
• Monitor blood pressure regularly, especially during dose escalation.
• Evaluate for signs of infection at the infusion site and catheter integrity.
• Use caution in patients with severe hepatic impairment or elevated liver enzymes.
• Adjust dosing in renal dysfunction, as clearance may be reduced.
• Counsel patients on proper storage, handling, and disposal of the infusion system.

Treprostinil may interact with other medications that affect vascular tone, platelet function, or drug metabolism. Awareness of these interactions helps optimize therapy.

Avoid

• Concomitant use of potent vasodilators such as nitroglycerin that can cause severe hypotension.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may increase bleeding risk.
• Epoprostenol or other prostacyclin analogs, which can lead to additive vasodilatory effects.

Use with caution

• Phosphodiesterase‑5 inhibitors, as combined therapy may enhance vasodilation and require dose adjustments.
• Endothelin receptor antagonists, which can affect hemodynamics when used together.
• Anticoagulants, because treprostinil can inhibit platelet aggregation and increase bleeding tendency.
• CYP2C8 substrates (e.g., repaglinide) that may have altered metabolism.